Dr Dean Craig Singleton

BSc(Hons), PhD


Dean Singleton obtained his BSc(Hons) in Biomedical Sciences at the University of Auckland and his PhD in Molecular Medicine and Pathology at the University of Auckland under the supervision of Associate Professor Adam Patterson and Professor Bill Wilson. He then completed a postdoctoral fellowship in the laboratory of Professor Adrian Harris at the Weatherall Institute of Molecular Medicine, University of Oxford, investigating transcriptional responses to tumour hypoxia. In 2014 he joined the laboratory of Dr Susanne Müller-Knapp in the Nuffield Department of Medicine, University of Oxford, developing chemical probes to target epigenetic proteins. In 2015 he was awarded the Rodney and Elaine Davies Cancer Research Fellowship to return to the University of Auckland.

Dr Singleton’s primary interest is in the development of antitumour agents that target tumour hypoxia with a focus on blocking the epigenetic reprogramming implicated in transcriptional responses to hypoxia.

Research | Current

My research aims to identify and develop new approaches to treat cancer. These projects include a combination of medicinal chemistry, functional genomics, cancer metabolism and cellular biology.

My current projects include:

  • Can targeting glutamine metabolism destabilise HIF-1α in Triple receptor Negative Breast Cancer?
  • Can targeting PERK (an immunosuppressive stress kinase) in immune cells restore antitumour immunity and enhance the activity of immune checkpoint therapy?
  • Can whole genome CRISPR/Cas9 screens identify genes that are required for growth and survival of IDH1 mutant brain cancers?

Teaching | Current

MEDSCI 302 -  Cancer Biology

MEDSCI 714 -  Advanced Cancer Biology

MEDSCI 700 -  Drug Discovery Biology


Selected publications and creative works (Research Outputs)

  • Liew, L. P., Singleton, D. C., Wong, W. W., Cheng, G. J., Jamieson, S. M. F., & Hay, M. P. (2019). Hypoxia‐Activated Prodrugs of PERK Inhibitors. Chemistry - An Asian Journal, 14 (8), 1238-1248. 10.1002/asia.201801826
    URL: http://hdl.handle.net/2292/48401
    Other University of Auckland co-authors: Lydia Liew, Way Wong, Stephen Jamieson, Michael Hay
  • Leung, E. Y., Askarian-Amiri, M. E., Singleton, D. C., Ferraro-Peyret, C., Joseph, W. R., Finlay, G. J., ... Marshall, E. (2018). Derivation of Breast Cancer Cell Lines Under Physiological (5%) Oxygen Concentrations. FRONTIERS IN ONCOLOGY, 810.3389/fonc.2018.00425
    URL: http://hdl.handle.net/2292/45763
    Other University of Auckland co-authors: Euphemia Leung, Wayne Joseph, Graeme Finlay, Stefan Bohlander, Purvi Kakadiya
  • Liew, L. P., Wong, W. W., Singleton, D. C., Jamieson, S. M. F., Flanagan, J. U., Koumenis, C., & Hay, M. P. (2017). The development of hypoxia-selective prodrugs of the PERK inhibitor. Paper presented at 15th International Tumor Microenvironment Workshop, Miami, Florida. 27 April - 29 April 2017.
    URL: http://hdl.handle.net/2292/34511
    Other University of Auckland co-authors: Lydia Liew, Way Wong, Stephen Jamieson, Jack Flanagan, Michael Hay
  • McIntyre, A., Hulikova, A., Ledaki, I., Snell, C., Singleton, D., Steers, G., ... Wigfield, S. (2016). Disrupting hypoxia-induced bicarbonate transport acidifies tumor cells and suppresses tumor growth. Cancer Research, 76 (13), 1-12. 10.1158/0008-5472.CAN-15-1862
  • Singleton, D. C., Rouhi, P., Zois, C. E., Haider, S., Li, J. L., Kessler, B. M., ... Harris, A. L. (2015). Hypoxic regulation of RIOK3 is a major mechanism for cancer cell invasion and metastasis. Oncogene, 34 (36), 4713-4722. 10.1038/onc.2014.396
  • Clark, P. G., Vieira, L. C., Tallant, C., Fedorov, O., Singleton, D. C., Rogers, C. M., ... Müller S (2015). LP99: Discovery and synthesis of the first selective BRD7/9 bromodomain Inhibitor. Angewandte Chemie - International Edition, 54 (21), 6217-6221. 10.1002/anie.201501394
  • Pettersen, E. O., Ebbesen, P., Gieling, R. G., Williams, K. J., Dubois, L., Lambin, P., ... Langdon, S. P. (2015). Targeting tumour hypoxia to prevent cancer metastasis. From biology, biosensing and technology to drug development: The METOXIA consortium. Journal of Enzyme Inhibition and Medicinal Chemistry, 30 (5), 689-721. 10.3109/14756366.2014.966704
  • Hay, D. A., Fedorov, O., Martin, S., Singleton, D. C., Tallant, C., Wells, C., ... Rogers, C. M. (2014). Discovery and optimization of small-molecule ligands for the CBP/p300 bromodomains. JACS: Journal of the American Chemical Society, 136 (26), 9308-9319. 10.1021/ja412434f


Contact details

Primary office location

M&HS BUILDING 504 - Bldg 504
Level 0, Room 001
New Zealand

Web links